Neoadjuvant BO-112 and hypofractionated radiation therapy with or without nivolumab in soft tissue sarcoma: preclinical and phase 1 results

By afschroeder • March 6, 2026

Deng J, Pal A, Testa S, Xu JW, Tran LM, Graham DS, Hargil A, Subramanian A, Campbell KM, Limsuwannarot S, Chumpitaz Lavalle Á, Chin SC, Kremer S, Tariveranmoshabad M, Ewongwo A, Silvia SNR, Ogana H, Nemat-Gorgani N, Dubinett SM, Jaycox JR, Felix C, Schaue D, Nelson SD, Levine B, Motamedi K, Ghazikhanian V, Chmielowski B, Reddy V, Singh AS, Trnkova ZJ, Good Z, Quintero M, Crompton JG, Bernthal N, Eilber FC, Moding EJ, Kalbasi A. Neoadjuvant BO-112 and hypofractionated radiation therapy with or without nivolumab in soft tissue sarcoma: preclinical and phase 1 results. Cancer Discov. 2026 Mar 5. doi: 10.1158/2159-8290.CD-25-1132. Epub ahead of print. PMID: 41784328.

Tags: Hematology/Oncology, Publications, Pulmonary, Critical Care & Sleep Medicine, Veterans Administration

Related Posts

Epcoritamab plus rituximab, dexamethasone, cytarabine, oxaliplatin/carboplatin induces deep and durable responses in transplant-eligible patients with relapsed or refractory diffuse large B-cell lymphoma: results from the EPCORE NHL-2 trial

Abrisqueta P, Karimi YH, Morillo D, Cordoba R, Phillips T, De Vos S, Nijland M, Offner F, Andersson PO, Brody J, Cheah CY, Prieto PG,[...]

Osimertinib plus datopotamab deruxtecan in patients with EGFR-mutated advanced NSCLC post-progression on first-line osimertinib: ORCHARD

Riess JW, Yu HA, Le X, de Langen AJ, Cho BC, Piotrowska Z, Hendriks LEL, Morabito A, Bonanno L, Brustugun OT, Halvorsen TO, Kim YJ,[...]

Trastuzumab deruxtecan in hormone receptor-positive, HER2-low/-ultralow metastatic breast cancer (DESTINY-Breast06): outcome analyses by time to progression on prior first-line endocrine therapy with CDK4/6 inhibitor and baseline burden of disease

Curigliano G, Hu X, Dent R, Yonemori K, Barrios CH, Pierga JY, Puglisi F, Ferrero JM, Jung KH, Bagegni NA, Collignon J, Gil-Gil M, Wu[...]